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Background: Considerable heterogeneity has been observed in the selection and reporting of disease-specific
pediatric outcome measures in randomized controlled trials (RCTs). This makes interpretation of results and
comparison across trials challenging. Outcome measures in pediatric anaphylaxis trials have never previously been
systematically assessed. This systematic review (SR) identified and assessed outcome measures used in RCTs of
anaphylaxis treatment in children. As a secondary objective, this SR assessed the evidence for current treatment
modalities for anaphylaxis in the pediatric population.
Methods: We searched MEDLINE, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials
(CENTRAL), and CINAHL from 2001 until December 2012. We also searched websites listing ongoing trials. We
included randomized and controlled trials of anaphylaxis treatment in patients 0–18 years of age. Two authors
independently assessed articles for inclusion.
Results: No published studies fulfilled the inclusion criteria.
Conclusions: There is an alarming absence of RCTs evaluating the treatments for anaphylaxis in children. High
quality studies are needed and are possible to design, despite the severe and acute nature of this condition.
Consensus about the selection and validation of appropriate outcome measures will enhance the quality of
research and improve the care of children with anaphylaxis.
Trial registration: CRD42012002685Background
RCTs are the gold standard for clinical treatment effi-
cacy, and allow for evidence-based practice. Many
pediatric RCTs are published annually in high impact
journals, however, outcome measures in these trials
may not be valid or consistently reported [1-3]. If the
outcome measures used in clinical trials are not valid,
the results of the trials themselves are questionable.
Indeed, much heterogeneity in outcome selection and
reporting has been observed amongst clinical trials of
specific diseases [4,5].
In an effort to address the issue of outcomes report-
ing in pediatric trials, an interdisciplinary team of
researchers at the University of Alberta developed the
PORTal (Primary Outcomes Reporting in Trials) initia-
tive. In collaboration with COMET and StaRChild* Correspondence: svohra@ualberta.ca
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unless otherwise stated.Health, PORTal plans to develop a database of vali-
dated pediatric outcome measures that can be accessed
by child health researchers. Outcomes that should be
measured and reported in all clinical trials of a specific
condition, regardless of statistical significance, would
also help reduce the problem of outcome reporting
bias [6]. Uniform selection of outcomes would make
interpretation of results and comparison across trials
simpler, making meta-analyses more feasible [4].
According to a 2011 systematic review by Sinha et al.,
very few studies have addressed the appropriate selection
of outcomes for clinical research involving children [7].
This review also identified 13 conditions for which some
work has already been done to determine which out-
comes should be measured in pediatric clinical trials.
Since anaphylaxis was not amongst those conditions, an
assessment of the heterogeneity and quality of reporting
of outcome measures was considered useful.
Anaphylaxis is a serious and potentially fatal allergic
reaction with a rapid onset [8]. In 2005, an expert paneltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rubin et al. BMC Pediatrics 2014, 14:158 Page 2 of 8
http://www.biomedcentral.com/1471-2431/14/158published a set of three criteria defining anaphylaxis
[8]. The three criteria are: 1. Acute onset of illness with
involvement of skin, mucosal tissue, or both, AND at
least one other system involved (respiratory compromise,
OR cardiovascular compromise/associated end-organ
dysfunction); 2. Two or more of: skin-mucosal, respira-
tory, reduced BP/associated end-organ dysfunction,
gastrointestinal symptoms, occurring rapidly after ex-
posure to a likely allergen for that patient; 3. Reduced
blood pressure minutes to hours after exposure to a
known allergen for that patient. According to their
consensus, anaphylaxis is highly likely when any one of
these three criteria is fulfilled.
Anaphylaxis can be triggered by food, insect venom,
medication, latex, exercise, or unknown causes [9-16].
Regardless of the inciting cause, the final common path-
way is release of histamine and other mediators from mast
cells and basophils. Anaphylaxis may be fatal within
minutes, usually through cardiovascular or respiratory
compromise, or both [17-23]. Biphasic reactions, de-
fined as a recurrence of anaphylactic symptoms after
initial resolution, can occur 1 h to 72 h after the initial
onset of symptoms [24].
In addition to epinephrine, H1-receptor antagonists and
H2-receptor antagonists (i.e. antihistamines such as cetiri-
zine and ranitidine, respectively), and corticosteroids are
often used in acute therapy and after discharge. Most
experts recommend these additional therapies despite
limited data to support their use since these drugs are
thought to be unlikely to cause harm and theoretically have
some added benefit in the resolution of symptoms [23].
The most recent systematic reviews of anaphylaxis
treatment, published in the Cochrane database, indicate
an alarming paucity of high quality evidence supporting
currently accepted treatments, including epinephrine,
glucocorticoids, antihistamines and supportive care (e.g.
oxygen, fluid resuscitation, raising legs above the head,
inhaled bronchodilators) [25-27].
The present systematic review was planned to iden-
tify and assess the outcome measures used in RCTs
of anaphylaxis treatment in children. As a secondary
objective, this systematic review would assess the evi-




The search strategy was developed in conjunction with
a clinical librarian. The following electronic biblio-
graphic databases were searched: MEDLINE, EMBASE,
The Cochrane Library and Cochrane Central Register
of Controlled Trials (CENTRAL), and CINAHL.
The search strategy included all terms relating to the
condition (anaphylaxis). The terms were combined withthe Cochrane MEDLINE filter for controlled trials of
interventions, and pediatrics (children/infants/adolescents).
The search strategy for MEDLINE is available in the
Appendix. The search terms were adapted for use with
other bibliographic databases in combination with
database-specific filters, where these were available.
The search was limited to English-language studies, and
studies published between January 2001 and December
31, 2012, in order to assess for improved quality of
outcome reporting in studies published post-CONSORT
(Consolidated Standards of Reporting Trials) guide-
lines [28].
The following websites were searched for ongoing/regis-
tered clinical trials on the topic: https://portal.nihr.ac.uk/
Pages/NRRArchive.aspx; http://clinicaltrials.gov/; www.
controlled-trials.com; http://www.anzctr.org.au/.Study selection
Two reviewers (TR, JC) independently screened titles
and abstracts of identified references. Both reviewers
also independently searched the websites for ongoing
trials. Studies were included if they were a. RCTs; b.
involved pediatric patients (0-18 years of age inclusive);
c. investigated anaphylactic reactions from any triggering
cause (including food, insect venom, medication, bio-
logic, diagnostic agent, vaccinations, latex, exercise, or
idiopathic cause) and; d. compared any acute treatment
of anaphylaxis (pharmacologic, supportive measures)
with any control treatment (including, but not limited to
placebo). Any modality studied for the acute treatment
of anaphylaxis was considered, including: epinephrine of
any dose, timing and mode of administration; glucocorti-
coids of any dose, timing and mode of administration;
inhaled beta-2 agonists; antihistamines (H1 and/or H2
antihistamines); novel treatments; and observation/ sup-
portive care by skilled professionals in a healthcare set-
ting. Studies focusing on the prevention of anaphylaxis
(e.g. by immunotherapy) were excluded. Any and all out-
come measures used in current research of pediatric
anaphylaxis were included.Results
In total, our combined searches yielded 1996 citations
(see Figure 1). After screening, no studies were identified
that met all inclusion criteria. The vast majority of refer-
ences were not articles primarily relating to anaphylaxis,
or anaphylaxis treatment. References relating to specif-
ically to anaphylaxis treatment were reviews, system-
atic reviews, case reports, case series, and other types
of observational (usually retrospective) studies. There
were a number of controlled trials relating to anaphyl-
axis prevention, but none about treatment of pediatric
anaphylaxis.
Figure 1 Search flow diagram.
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Current Controlled Trials, and Clinical Trials using
anaphylaxis as a keyword identified no useful proposed,
ongoing, or completed studies.
One study registered in the Australia/New Zealand
Clinical Trials Registry in March 2011 met inclusion
criteria. This was an RCT of intravenous versus intra-
muscular (control) epinephrine treatment of acute
anaphylaxis in an emergency department in patients
15 years of age and older. The status of the trial in the
database indicated that the investigators were not yet
recruiting as of April 2011. Attempts to contact the
primary investigator via email were unsuccessful [29].
One additional study identified through the search was
an RCT comparing the sedative properties of cetirizine
versus diphenhydramine in the treatment of acute food-
induced allergic reactions in children [30]. The full text
of this article was extracted and reviewed and, ultim-
ately, excluded because the condition being studied was
not anaphylaxis, but rather all allergic reactions.
Discussion
This review failed to uncover any completed randomized
or controlled trials of pediatric anaphylaxis treatments
despite a broad search strategy. Therefore, the primary
objective could not be determined. In the one planned
RCT of IV versus IM epinephrine, the two main out-
comes proposed were resolution of the main clinicalfeatures of anaphylaxis (defined according to consensus
definition), [29], or improvement on an ordinal sever-
ity scale at 15 minutes. The planned secondary outcome
was adverse effects at 15 and 60 minutes. The definition of
anaphylaxis and its resolution were current, and the out-
come measures proposed are appropriate.
Clinical implications
Epinephrine remains the treatment of choice for ana-
phylaxis although there are no RCTs supporting its use.
Epinephrine has been relatively well investigated in
both children and adults in observational studies [31],
RCTs involving non-anaphylactic patients [32-35], epi-
demiologic studies [9,36,37], fatality studies [18,19,38],
and in vitro and animal studies [22,39]. Many of these
studies have identified that delays in instituting treat-
ment with epinephrine are associated with risks of
mortality [40-42].
On the basis of this evidence, an expert panel pub-
lished the 2011 National Institute of Allergy and Infec-
tious Diseases (NIAID) guidelines for acute treatment of
anaphylaxis. They recommended immediate use of
intramuscular epinephrine, concluding that the benefits
far outweigh the risks [43]. They concluded that the
quality of evidence is moderate, although the contribu-
tion of expert opinion is still significant. NIAID dosing
recommendations for Epinephrine 1:1000 solution for
children and adults is based on pharmacologic studies.
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and 0.3 mg for children over 25 kg. They also suggest
repeat dosing every 5-15 minutes as needed.
While second line medications such as corticoste-
roids and antihistamines are still recommended as
adjunctive treatments, the expert panel did note the
lack of evidence for these modalities. Possible reasons
for continuing poorly investigated interventions in
pediatrics include: “biological plausibility” of the inter-
vention, extrapolation of data from adult studies,
acceptance of lower quality research, lack of known
significant harm of the intervention, and a need to do
“something” rather than nothing in acute situations.
Perceived concerns about medico-legal liability may
also contribute to provision of treatments with no
known benefits and lack of perceived harm. In their
report, NIAID identified several knowledge gaps, in-
cluding the role of adjunctive treatments for anaphyl-
axis (steroids, antihistamines and others), appropriate
treatment of biphasic or protracted reactions, and the
benefits and risks of alternative routes of epinephrine
dosing (e.g. sublingual).
Studies have found that, despite epinephrine being the
only anaphylaxis treatment with demonstrated efficacy
in preventing mortality, it is not used consistently, and
second-line or adjunctive medications are more often
administered, sometimes before epinephrine. For ex-
ample, a retrospective cross-sectional study of patients
seen in a pediatric emergency department over a 5-year
period with a final diagnosis of anaphylaxis showed a
rate of epinephrine administration of only 54%. This was
less than the rate of corticosteroids (78%) and H1 and/or
H2 receptor antagonists (92%) [44].
The administration of adjunctive medications can
potentially delay the use of other, perhaps more effect-
ive treatment modalities and therefore might contrib-
ute to morbidity and mortality. Furthermore, both
antihistamines and steroids have adverse effects and
costs, and may theoretically mask important markers
of ongoing anaphylaxis risk. Recurrent dosing of both
epinephrine and steroids in the emergency department
also carries risks of systemic side effects. These factors
need to be weighed against the potential benefit of
these treatments.
Limitations
A limitation of the current systematic review is that it
was limited to studies done in the last twelve years.
This time frame was considered acceptable as there are
recent systematic reviews investigating anaphylaxis
treatments that found no RCTs in databases extending
up to thirty years into the past. Further limitations
include the exclusion of non-English and non-registered
trials.Research implications
There are a number of possibilities to explain the current
gap in research. Firstly, there are clearly ethical issues
involved in obtaining informed consent (or deferring
consent) in emergency situations. Secondly, current
anaphylaxis treatments are usually life saving, generally
safe, and well established, contributing to the perceived
lack of relevance of specific questions regarding phar-
macotherapy. Thirdly, due to the clinical nature of
anaphylaxis diagnosis, lack of accepted standards for
determining degree of severity [45,46] and lack of object-
ive point of care testing, study design can be challenging.
Fourthly, a large number of patients is required for an
adequately powered study assessing an uncommon
condition such as pediatric anaphylaxis, and would
require considerable resources over a long period of time.
Additionally, prospectively collected data is essential and
more valid in establishing accurate rates of adverse effects
of pharmacotherapy and other interventions, but is
also costly. Finally, pediatric research is associated with
additional challenges, including a vulnerable and smaller
population, the challenge of obtaining informed consent/
assent from children, and the need to address family-
centered outcomes in both treatment and investigation.
Institutional review boards serve to protect the pub-
lic from the harms of unethical research, but must
balance this responsibility against the imperative of
advancing medical care through high quality investiga-
tion. Emergency situations, when consent cannot be
obtained readily without compromising patient care,
pose a particular challenge for researchers. Neverthe-
less, resuscitation research, which by its nature must
be studied in emergency situations, is absolutely neces-
sary, and ultimately benefits patient care.
Multiple organizations around the world have recog-
nized the importance of resuscitation research, and the
challenges of obtaining individual informed consent in
this context. Therefore, guidelines for ethical research
involving institutional (or deferred) consent have been
developed. For example, a research ethics board may
allow research that involves medical emergencies to be
carried out without the consent of participants, or of
their authorized third party, if a number of conditions
are met [47-49]. For example, a waiver of consent may
be obtained if: a. the research involves no more than
minimal risk to the subjects; b. the waiver or alteration
will not adversely affect the rights and welfare of the
subjects; c. the research could not practicably be carried
out without the waiver; d. whenever appropriate, the
subjects are provided with additional pertinent informa-
tion after participation [49].
Although rare, placebo-controlled trials done in emer-
gency situations exist [50,51]. It is certainly possible to
design trials studying anaphylaxis in children that meet
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lifesaving treatment, such as epinephrine, would clearly
be unethical, conducting a trial to determine the optimal
dosing interval or route of administration, would be un-
likely to involve greater risk to the patient if the control
is the standard of care (intramuscular epinephrine). In
this situation, the research also offers a possibility of
direct benefit to the participant. A placebo-controlled
trial of antihistamines, on the other hand, could be both
ethical and feasible.
There are numerous potential outcome measures that
should be used and reported in all future research of
anaphylaxis treatment in children. Selecting valid and
clinically relevant outcomes is of paramount importance.
Potential outcome measures include: mortality rate; inci-
dence of biphasic reaction and prolonged anaphylaxis;
rates of interventions other than study drug (e.g. beta
agonists, steroids, antihistamines, non-epinephrine vaso-
active drugs); hospitalization rate; length of emergency
department visit; length of hospital stay; rate of re-
presentation to hospital; pediatric specific measures
(e.g. pediatric health/mental health scales); and inci-
dence of any adverse events reported for any treatment
delivered. The design and validation of a universal ana-
phylaxis severity rating scale could be of potential
benefit, and may offer a useful outcome measure.
Future research in anaphylaxis should also collect infor-
mation regarding discharge practices for cases of anaphyl-
axis, including prescriptions for injectable epinephrine
devices, advice for optimization of asthma if relevant,
referral to allergists, and anaphylaxis education.
Conclusions
There is an alarming absence of RCTs evaluating the
treatments for anaphylaxis in children. High quality
studies are needed and are possible to design despite the
severe and acute nature of this condition. Future trials
should ensure appropriate comparator therapy that sat-
isfies the ethical constraints inherent in resuscitation
research and studies involving children, and the selec-
tion of appropriate outcome measures.
Research designs other than RCTs are still useful and
can enhance the evidence for anaphylaxis treatment.
Practice surveys in different settings, observational stud-
ies, and qualitative patient/family-centered studies are
feasible and easy to design. Based on the results of this
systematic review, it is impossible to make conclusive
recommendations regarding optimal dosing, timing, or
mode of administration of epinephrine for anaphylaxis.
Furthermore, there is no evidence from RCTs supporting
or refuting the use of common adjunctive treatments,
such as corticosteroids and antihistamines, in the acute
treatment of anaphylaxis, in preventing biphasic reac-
tions, or after discharge from the ER. Until high-qualitystudies are designed and executed, current practices and
guidelines on the management of anaphylaxis will con-
tinue to be based on lower quality evidence and on the
consensus opinions of experts.
The careful selection and validation of outcome mea-
sures for future studies on pediatric anaphylaxis will sup-
port meaningful research and better treatment of children
with this condition. Consistent universal reporting of these
outcomes will protect against outcome reporting bias.
Appendix
Cochrane SR
1. anaphylaxis.mp. [mp=title, short title, abstract, full
text, keywords, caption text]
2. anaphylactic shock.mp. [mp=title, short title, ab-
stract, full text, keywords, caption text]
3. anaphyla*.mp. [mp=title, short title, abstract, full
text, keywords, caption text]
4. systemic anaphylaxis.mp. [mp=title, short title, ab-
stract, full text, keywords, caption text]
5. idiopathic anaphylaxis.mp. [mp=title, short title, ab-
stract, full text, keywords, caption text]
6. 1 or 2 or 3 or 4 or 5
7. (child* or infan* or adolescen*).mp. [mp=title, short
title, abstract, full text, keywords, caption text]
8. 6 and 7
9. limit 8 to last 10 years
Cochrane Central
1. exp Anaphylaxis/
2. anaphylactic shock.mp. [mp=title, original title, ab-
stract, mesh headings, heading words, keyword]
3. anaphylact*.mp. [mp=title, original title, abstract,
mesh headings, heading words, keyword]
4. anaphylax*.mp. [mp=title, original title, abstract,
mesh headings, heading words, keyword]
5. acute systemic allergic react*.mp. [mp=title, original
title, abstract, mesh headings, heading words, keyword]
6. (acute adj3 allerg*).mp. [mp=title, original title, ab-
stract, mesh headings, heading words, keyword]
7. idiopathic anaphylaxis.mp. [mp=title, original title,
abstract, mesh headings, heading words, keyword]
8. systemic anaphylaxis.mp. [mp=title, original title,
abstract, mesh headings, heading words, keyword]
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. (child* or infan* or adolescen*).mp. [mp=title, original
title, abstract, mesh headings, heading words, keyword]
11. 9 and 10
12. limit 11 to yr="2001 - 2011"
13. limit 12 to randomized controlled trial
CINAHL
S1 TX randomized controlled trail
S2 TX Clinical trials






S8 S1 or S2 or S3 or S4 or S5 or S6 or S7
S9 MW Animals
S10 MW Human
S11 9 not (9 and 10)
S12 8 not 11
S13 MW Anaphylaxis
S14 MW Anaphylactic shock
S15 TX anaphylact*
S16 TX anaphylax*
S17 TX "acute systemic allergic react*"
S18 TX acute adj3 allerg*
S19 TX idiopathic anaphylaxis
S20 TX systemic anaphylaxis
S21 S13 or S14 or S15 or S16 or S17 or S18 or S19 or
S20
S22 (S13 or S14 or S15 or S16 or S17 or S18 or S19 or
S20) and (S12 and S21)
S24 Narrow by SubjectAge: - Infant: 1-23 months
Narrow by SubjectAge: - Child, Preschool: 2-5 years
Narrow by SubjectAge: - Adolescent: 13-18 years
Narrow by SubjectAge: - Child: 6-12 years
S25 Limiters - Published Date from: 20010101-20111231
S26 Limiters - English Language
Embase








9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. animal/
11. human/
12. 10 not (10 and 11)
13. 9 not 12
14. anaphylactic shock.mp. or exp anaphylactic shock/
15. anaphylact*.mp. [mp=title, abstract, subject head-
ings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
16. anaphylax*.mp. [mp=title, abstract, subject head-
ings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
17. acute systemic allergic react*.mp. [mp=title, abstract,
subject headings, heading word, drug trade name,original title, device manufacturer, drug manufac-
turer, device trade name, keyword]
18. (acute adj3 allerg*).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
19. idiopathic anaphylaxis.mp. [mp=title, abstract, sub-
ject headings, heading word, drug trade name, ori-
ginal title, device manufacturer, drug manufacturer,
device trade name, keyword]
20. systemic anaphylaxis.mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device
trade name, keyword]
21. 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 13 and 21
23. (infan* or child* or adolescen*).ti,ab,kw,tw.
24. 22 and 23
25. limit 24 to english language
26. limit 25 to yr="2001 - 2011"
Medline











12. 10 not (10 and 11)
13. 9 not 12
14. anaphylactic shock.mp. or exp Anaphylaxis/
15. anaphylact*.mp. [mp=protocol supplementary con-
cept, rare disease supplementary concept, title, ori-
ginal title, abstract, name of substance word,
subject heading word, unique identifier]
16. anaphylax*.mp. [mp=protocol supplementary con-
cept, rare disease supplementary concept, title, ori-
ginal title, abstract, name of substance word,
subject heading word, unique identifier]
17. acute systemic allergic react*.mp. [mp=protocol
supplementary concept, rare disease supplementary
concept, title, original title, abstract, name of sub-
stance word, subject heading word, unique identifier]
18. (acute adj3 allerg*).mp. [mp=protocol supplemen-
tary concept, rare disease supplementary concept,
title, original title, abstract, name of substance
word, subject heading word, unique identifier]
19. idiopathic anaphylaxis.mp. [mp=protocol supplemen-
tary concept, rare disease supplementary concept,
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subject heading word, unique identifier]
20. systemic anaphylaxis.mp. [mp=protocol supple-
mentary concept, rare disease supplementary con-
cept, title, original title, abstract, name of substance
word, subject heading word, unique identifier]
21. 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 13 and 21
23. limit 22 to "all child (0 to 18 years)"
24. limit 23 to english language
25. limit 24 to yr="2001 - 2011"
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